TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity

Haemophilia

Volumn 22, Issue 6, 2016, Pages 873-879

  Mahlangu, J ^a   Paz, P ^b   Hardtke, M ^c   Aswad, F ^b   Schroeder, J ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b BAYER CORPORATION   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

BAY 86 6150; bypass agent; haemophilia; immunogenicity; inhibitor; safety

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BAY 866150; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG; BAY 86-6150; BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EPITOPE MAPPING; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; MALE; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; FEMALE; IMMUNOLOGY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; FACTOR VIIA; FEMALE; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84994338273     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12994     Document Type: Article

References (26)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47.
2. Kruse-Jarres R. Inhibitors: our greatest challenge. Can we minimize the incidence? Haemophilia 2013; 19(Suppl 1): 2–7.
3. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011; 72: 553–62.
4. DiMichele DM. Inhibitors in hemophilia: a primer. Treatment of Hemophilia. 4th edn. Montreal, Canada: World Federation of Hemophilia, 2008.
5. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546–51.
6. Mahlangu JN, Coetzee MJ, Laffan M et al. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost 2012; 10: 773–80.
7. Zollner S, Schuermann D, Raquet E et al. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost 2014; 12: 220–8.
8. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA 2001; 98: 13583–8.
9. Mahlangu JN, Weldingh KN, Lentz SR et al. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost 2015; 13: 1989–98.
10. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S. NetMHCIIpan-2.0 – Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 2010; 6: 9.
11. Mahlangu J, Koh PL, Ng HJ, Lissitchkov T, Hardtke M, Schroeder J. The TRUST trial: anti-drug antibody formation in a patient with hemophilia with inhibitors after receiving the activated factor VII product BAY 86-6150. Presented at: American Society of Hematology; December 7–10, 2013; New Orleans, LA.
12. Gorovits B, Wakshull E, Pillutla R, Xu Y, Manning MS, Goyal J. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J Immunol Methods 2014; 408: 1–12.
13. Thim L, Bjoern S, Christensen M et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785–93.
14. Millar DS, Kemball-Cook G, McVey JH et al. Molecular analysis of the genotype-phenotype relationship in factor VII deficiency. Hum Genet 2000; 107: 327–42.
15. Herrmann FH, Wulff K, Auerswald G et al. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia 2009; 15: 267–80.
16. Wulff K, Herrmann FH. Twenty two novel mutations of the factor VII gene in factor VII deficiency. Hum Mutat 2000; 15: 489–96.
17. Delmer A, Horellou MH, Andreu G et al. Life-threatening intracranial bleeding associated with the presence of an antifactor VII autoantibody. Blood 1989; 74: 229–32.
18. Okajima K, Ishii M. Life-threatening bleeding in a case of autoantibody-induced factor VII deficiency. Int J Hematol 1999; 69: 129–32.
19. Astermark J, Ekman M, Berntorp E. Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors. Br J Haematol 2002; 119: 342–7.
20. Branchini A, Baroni M, Pfeiffer C et al. Coagulation factor VII variants resistant to inhibitory antibodies. Thromb Haemost 2014; 112: 972–80.
21. Borhany M, Delbes C, Giansily-Blaizot M et al. A new report of FVII-inhibitor in a patient suffering from severe congenital FVII deficiency. Haemophilia 2015; 21: e336–8.
22. Shibeko AM, Woodle SA, Mahmood I, Jain N, Ovanesov MV. Predicting dosing advantages of factor VIIa variants with altered tissue factor-dependent and lipid-dependent activities. J Thromb Haemost 2014; 12: 1302–12.
23. Ljung R, Karim FA, Saxena K et al. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors. J Thromb Haemost 2013; 11: 1260–8.
24. Novo Nordisk. Interim financial report for the period 1 January 2011 to 30 September 2011. Available at: https://www.novonordisk.com/bin/getPDF.1558329.pdf. Accessed April 5, 2016.
25. Novo Nordisk. Novo Nordisk discontinues development of vatreptacog alfa following analysis of phase 3 results. Available at: http://hugin.info/2013/R/1644628/529831.pdf. Accessed April 5, 2016.
26. Lentz SR, Ehrenforth S, Karim FA et al. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost 2014; 12: 1244–53.